Company Profile
Structure Therapeutics Stock Price, News & Analysis
- Ticker:
- GPCR
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
52.62 USD (+4.14%)
Close
Last updated: August 6, 2026
2.64B USD
Market cap
Why the stock is moving
The latest monitored company update is “Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights.” The corresponding closing-price reaction is not yet available.
Company overview
Structure-Based Metabolic Drug Discovery
Structure Therapeutics develops oral small molecules against validated metabolic targets using structure-based drug design. Its franchise is intended to offer oral alternatives to injectable peptide therapies.
Aleniglipron
Aleniglipron is an oral GLP-1 receptor agonist in development for obesity and type 2 diabetes. Phase 2 studies are evaluating long-term weight loss, body composition and metabolic effects ahead of Phase 3 development.
ACCG-2671
ACCG-2671 is an oral small-molecule amylin-receptor agonist in Phase 1 development. The study includes single- and multiple-ascending-dose evaluation.
ACCG-3535
ACCG-3535 is a second oral amylin candidate preparing to enter Phase 1 testing, providing Structure with a follow-on molecule in the same therapeutic class.
Combination-Oriented Franchise
Structure is developing its GLP-1 and amylin candidates as standalone therapies and potential oral combinations, creating multiple development paths within obesity and metabolic disease.
Future catalysts
Initiation of Phase 3 development for aleniglipron in the third quarter of 2026.
ACCESS open-label-extension data in the third quarter of 2026.
Initial Phase 1 single-ascending-dose data for ACCG-2671 and initiation of multiple-ascending-dose testing in the third quarter of 2026.
Body-composition and type 2 diabetes/obesity data for aleniglipron in the fourth quarter of 2026.
Initiation of a Phase 1 study of ACCG-3535 in the fourth quarter of 2026.
Recent news
- 01
Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
Source: Structure Therapeutics
- 02
- 03
Structure Therapeutics Announces Participation in Upcoming Investor Conferences
Source: Structure Therapeutics
- 04
Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
Source: Structure Therapeutics
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Structure Therapeutics (GPCR)?
Structure Therapeutics (GPCR) most recently closed at 52.62 USD, a +4.14% move versus the previous session.
What is the market cap of Structure Therapeutics (GPCR)?
Structure Therapeutics currently has a market capitalization of 2.64B USD on BioPharmSignal.
What does Structure Therapeutics do?
Structure-Based Metabolic Drug Discovery Structure Therapeutics develops oral small molecules against validated metabolic targets using structure-based drug design. Its franchise is intended to offer oral alternatives to injectable peptide therapies. Aleniglipron Aleniglipron is an oral GLP-1 receptor agonist in development for obesity and type 2 diabetes....
On which exchange is GPCR stock listed?
Structure Therapeutics (GPCR) is associated with NASDAQ, United States, Biopharma.
What is GLP-1?
Aleniglipron Aleniglipron is an oral GLP-1 receptor agonist in development for obesity and type 2 diabetes.
Which conditions is Structure Therapeutics targeting with GLP-1?
Structure Therapeutics is associated with metabolic disease, obesity, diabetes based on its company overview and current catalyst commentary.
How does Structure Therapeutics describe recent progress with GLP-1?
Initiation of Phase 3 development for aleniglipron in the third quarter of 2026. ACCESS open-label-extension data in the third quarter of 2026. Initial Phase 1 single-ascending-dose data for ACCG-2671 and initiation of multiple-ascending-dose testing in the third quarter of 2026. Body-composition and type 2 diabetes/obesity data for aleniglipron in the...
What is ACCG-2671?
ACCG-2671 ACCG-2671 is an oral small-molecule amylin-receptor agonist in Phase 1 development.